Gilead swoops in with $567M deal to buy CAR-T 2.0 play­er Cell De­sign Labs

Gilead has swooped in on the first of sev­er­al planned new buy­outs to build out its CAR-T op­er­a­tions ac­quired in the $12 bil­lion Kite buy­out. And it’s start­ing with a com­pa­ny that Kite’s Arie Bellde­grun be­lieved held the key to the next-gen cell ther­a­pies that will even­tu­al­ly over­take the pi­o­neers.

The com­pa­ny is Cell De­sign Labs, found­ed on the tech­nol­o­gy or­ches­trat­ed by UC San Fran­cis­co star re­searcher Wen­dell Lim. Gilead has agreed to buy the com­pa­ny, launched with on­ly $34 mil­lion in in­vest­ment cash from Klein­er Perkins, Kite and oth­ers, for up to $567 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.